Lightpoint Medical will collaborate with Telix Pharmaceuticals to improve its cancer detection probe

Lightpoint Medical has signed a strategic collaboration agreement with Telix Pharmaceuticals, a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly targeted radiation.

The two companies will collaborate to combine Telix's imaging agents with Lightpoint Medical's SENSEI probe in order to create a more precise technique to help surgeons detect cancer that might not otherwise be found during surgery, or conversely, confirm the absence of disease to help surgeons retain healthy, functional tissue.

The technology is primarily focused on prostate cancer, but has a potential to be used across a range of major cancer types.